Cidara Therapeutics Inc
CDTX
Company Profile
Business description
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company’s portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.
Contact
6310 Nancy Ridge Drive
Suite 101
San DiegoCA92121
USAT: +1 858 752-6170
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
73
Stocks News & Analysis
stocks
Progress in UK expansion for undervalued ASX share
Guidance reaffirmed and UK implementation on track.
stocks
The sectors set to soar on government spending
Governments worldwide love to spend more money, and there are no signs that it will change any time soon.
stocks
Chart of the Week: How private companies are reshaping public markets
Our latest take from the US Manager Research team.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,108.30 | 17.80 | 0.20% |
| CAC 40 | 8,074.23 | 6.70 | 0.08% |
| DAX 40 | 24,049.74 | 100.63 | 0.42% |
| Dow JONES (US) | 47,311.00 | 225.76 | 0.48% |
| FTSE 100 | 9,777.08 | 62.12 | 0.64% |
| HKSE | 25,935.41 | 16.99 | -0.07% |
| NASDAQ | 23,499.80 | 151.16 | 0.65% |
| Nikkei 225 | 50,212.27 | 1,284.93 | -2.50% |
| NZX 50 Index | 13,631.94 | 10.96 | 0.08% |
| S&P 500 | 6,796.29 | 24.74 | 0.37% |
| S&P/ASX 200 | 8,836.80 | 27.00 | 0.31% |
| SSE Composite Index | 3,969.25 | 9.06 | 0.23% |